Related Experiment Video
Updated: Jan 4, 2026
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.3K
Quantifying Medication Exposure in Very Low Birth Weight Neonates.
Natalie L Davis1, Temitope O Akinmboni1, Sandra M Mooney2
1Department of Pediatrics, Division of Neonatology, University of Maryland School of Medicine, Baltimore, Maryland.
American Journal of Perinatology
|November 5, 2019
Summary
Very low birth weight (VLBW) infants in the NICU receive numerous medications, with over 30 drugs associated with higher risks. Male sex, lower birth weight, and longer hospital stays correlate with increased medication exposure in these vulnerable infants.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Pediatric Critical Care
Background:
- Very low birth weight (VLBW) infants face significant medication exposure during neonatal intensive care unit (NICU) stays.
- There is a lack of comprehensive pharmacokinetic and safety data for many medications used in VLBW infants.
- Understanding medication exposure is crucial for optimizing care and minimizing potential harm.
Purpose of the Study:
- To quantify medication exposure in VLBW infants.
- To identify risk factors associated with the highest quartile of medication exposure.
- To inform strategies for reducing medication burden in this population.
Main Methods:
- Retrospective review of clinical and demographic data for VLBW infants admitted to a level-IV NICU.
- Analysis of all medications administered during the hospital admission.
- Comparison of characteristics between infants in the highest quartile of medication use and the remaining infants.
Main Results:
- A cohort of 106 VLBW infants (mean birth weight 961g, gestational age 27.3 weeks) was analyzed.
- Infants received a median of 20 medications (range 4-72).
- Infants in the top quartile (≥30 medications) had higher odds of being male, having lower birth weight, longer length of hospital stay (LOHS), and developing bronchopulmonary dysplasia. Sepsis was not a significant factor.
Conclusions:
- VLBW infants experience substantial medication exposure in the NICU, including potentially unnecessary antibiotics and reflux medications.
- Male sex, certain comorbidities (e.g., necrotizing enterocolitis), and prolonged LOHS are linked to increased medication exposure.
- Raising awareness and implementing targeted interventions can help reduce medication exposure in VLBW infants.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
181
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
181
01:29Drug Dosing: Infants and Children
221
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
221
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
222
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
222
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
209
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
209
01:21Factors Affecting Drug Response: Overview
2.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
160
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
160